US 12,195,535 B2
Antibodies binding to VISTA at acidic pH
Robert J. Johnston, San Mateo, CA (US); Arvind Rajpal, San Francisco, CA (US); Paul O. Sheppard, Granite Falls, WA (US); Luis Borges, Houston, TX (US); Andrew Rankin, Redwood City, CA (US); Keith Sadoon Bahjat, Woodside, CA (US); Alan J. Korman, Piedmont, CA (US); Andy X. Deng, Princeton, NJ (US); Lin Hui Su, Somerville, MA (US); and Ginger Rakestraw, Somerville, MA (US)
Assigned to Five Prime Therapeutics, Inc., Thousand Oaks, CA (US); and Bristol-Myers Squibb Company, Princeton, NJ (US)
Filed by Five Prime Therapeutics, Inc., Thousand Oaks, CA (US); and Bristol-Myers Squibb Company, Princeton, NJ (US)
Filed on Feb. 1, 2023, as Appl. No. 18/162,991.
Application 18/162,991 is a division of application No. 16/493,712, granted, now 11,603,406, previously published as PCT/US2018/022230, filed on Mar. 13, 2018.
Claims priority of provisional application 62/636,746, filed on Feb. 28, 2018.
Claims priority of provisional application 62/471,196, filed on Mar. 14, 2017.
Prior Publication US 2024/0092907 A1, Mar. 21, 2024
Int. Cl. C07K 16/28 (2006.01)
CPC C07K 16/2812 (2013.01) [C07K 2317/34 (2013.01); C07K 2317/622 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)] 37 Claims
 
1. A nucleic acid comprising a polynucleotide sequence that encodes an antibody that specifically binds to human V-domain Ig Suppressor of T cell Activation (hVISTA), the antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region (VH) comprising VH CDR1, CDR2 and CDR3, which comprise amino acid positions 26-35, 50-66, and 99-112, respectively, of SEQ ID NO: 15, SEQ ID NO: 51, SEQ ID NO: 11, SEQ ID NO: 55, SEQ ID NO: 59, SEQ ID NO: 39, SEQ ID NO: 63, SEQ ID NO: 71, SEQ ID NO: 75, SEQ ID NO: 83, SEQ ID NO: 79, SEQ ID NO: 87, SEQ ID NO: 193, SEQ ID NO: 201, SEQ ID NO: 197, SEQ ID NO: 213, SEQ ID NO: 185, SEQ ID NO: 237, SEQ ID NO: 257, SEQ ID NO: 245, SEQ ID NO: 241, SEQ ID NO: 269, SEQ ID NO: 289, SEQ ID NO: 273, SEQ ID NO: 285, SEQ ID NO: 265, SEQ ID NO: 301, SEQ ID NO: 293, SEQ ID NO: 313, SEQ ID NO: 277, or SEQ ID NO: 305; and wherein the light chain comprises a light chain variable region (VL) comprising VL CDR1, CDR2 and CDR3, which comprise amino acid positions 24-35, 51-57, and 90-98, respectively, of SEQ ID NO: 68.